Susoctocog Alfa

證據等級: L5

預測適應症: 10 個

Susoctocog Alfa: From Acquired Hemophilia A to Acquired Coagulation Factor Deficiency

One-Sentence Summary

Susoctocog alfa (recombinant porcine Factor VIII, marketed elsewhere as Obizur/OBIZER) is an established treatment for bleeding episodes in Acquired Hemophilia A (AHA) — an indication confirmed by the clinical trial and literature evidence in this pack, even though it is not formally recorded in the regulatory data fields here. The TxGNN model separately proposes an extension to the broader disease concept of Acquired Coagulation Factor Deficiency, supported by 1 clinical trial and 10+ relevant publications that largely describe the drug's established AHA use. This drug is not currently marketed in Norway. Of the 10 diseases TxGNN predicted overall, only this indication (and the closely related "hemophilia" node) has real supporting evidence — the other 8 are flagged below as low-confidence, mechanistically unsupported predictions.

Quick Overview

Item	Content
Original Indication	Not recorded in regulatory data (data gap); clinical/literature evidence in this pack consistently identifies Acquired Hemophilia A as the drug's established use
Predicted New Indication	Acquired Coagulation Factor Deficiency (broader extension of the AHA mechanism)
TxGNN Prediction Score	99.74% (hemophilia node, rank 4) / 99.64% (acquired coagulation factor deficiency, rank 5)
Evidence Level	L3
Norway Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not available in the standard MOA field for this evidence pack (data gap). However, the clinical trial and literature evidence consistently describe susoctocog alfa as a recombinant, B-domain-deleted porcine sequence Factor VIII (rpFVIII). It works by directly replacing coagulation Factor VIII activity in patients whose endogenous human FVIII has been neutralized by autoantibodies — the defining pathology of Acquired Hemophilia A (AHA).

The TxGNN-predicted node "acquired coagulation factor deficiency" is mechanistically coherent with the drug's known action: it is essentially the same pathophysiological category as AHA (loss of a clotting factor due to acquired/autoimmune causes rather than genetic deficiency), and shares nearly all of its supporting literature with the AHA/hemophilia node. This is best understood as TxGNN correctly recovering and generalizing the drug's known mechanism, rather than identifying a truly novel biological pathway.

By contrast, the drug's original approved use (AHA) itself is missing from the structured regulatory fields in this pack — this appears to be a data capture gap rather than a genuine absence of an approved indication, since the pivotal Phase II/III trial (NCT04580407, referenced in PMID 39158833) and multiple real-world studies describe susoctocog alfa/Obizur as licensed specifically for bleeding episodes in adult AHA patients.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06461533	N/A (post-marketing surveillance)	Recruiting	25	Japanese all-case surveillance of Susoctocog Alfa (OBIZER) IV injection for bleeding events in Acquired Hemophilia A, monitoring side effects and effectiveness in real-world use

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27098420	2016	Review	Drugs	Comprehensive review: susoctocog alfa (Obizur) effective and generally well tolerated for serious bleeding in AHA in a multinational Phase II/III trial (n=28 evaluable)
38066923	2023	Review	Hematology Am Soc Hematol Educ Program	Diagnosis and laboratory monitoring approach for AHA, including FVIII inhibitor assessment
39245591	2024	Review	La Revue de médecine interne	2024 update on AHA pathophysiology, diagnosis, and hemostatic treatment options including rpFVIII
31298165	2019	Review	Current Pharmaceutical Design	Perioperative anesthetic considerations for new hemostatic agents, including recombinant porcine FVIII
39158833	2024	Phase II/III cohort	Int J Hematol	Japanese Phase II/III open-label study (NCT04580407) evaluating efficacy/safety of rpFVIII in adult AHA with severe bleeding
32698943	2020	Retrospective cohort	Blood Transfus	Largest Italian multicentre real-world registry of rpFVIII in 9 elderly AHA patients, describing efficacy and safety
37584309	2023	Post-authorization safety cohort	Haemophilia	Non-interventional real-world safety and effectiveness study of rpFVIII in AHA
40812597	2025	Cohort/PK	J Thromb Haemost	Pharmacokinetic strategies for precise FVIII control with susoctocog alfa dosing in AHA
37799011	2024	Cohort (lab methods)	Int J Lab Hematol	Agreement between one-stage and chromogenic assays for monitoring rpFVIII activity
36010349	2022	Cohort (lab methods)	Diagnostics	Analytical performance comparison of laboratory methods for measuring susoctocog-alfa activity

Other TxGNN-Predicted Indications (Low Confidence — Hold)

Beyond the AHA-related findings above, TxGNN's 8 remaining top-ranked predictions have no supporting clinical trials or literature and were explicitly flagged in the source evidence as mechanistically unsupported — the model appears to be linking these diseases via a general "bleeding tendency" semantic similarity rather than a specific pharmacological match:

Disease	TxGNN Score	Why Mechanism Doesn't Fit
Primary release disorder of platelets	99.94%	Pathology is platelet granule release, not FVIII deficiency
Pseudo-von Willebrand disease	99.93%	Caused by platelet GPIb abnormality, not FVIII
Glanzmann thrombasthenia	99.88%	GPIIb/IIIa platelet aggregation defect, unrelated to FVIII
Scott syndrome	99.60%	Platelet membrane scramblase defect, not FVIII
Bleeding diathesis (collagen receptor defect)	99.17%	Platelet adhesion (e.g., GPVI) defect, not FVIII
Hemorrhagic disorder (constitutional thrombocytopenia)	99.17%	Platelet count deficiency; FVIII replacement has no effect
Congenital Factor XIII deficiency	99.15%	Deficiency in a different clotting factor (XIII, not VIII)
Adenosine deaminase deficiency	99.04%	Immunodeficiency (SCID), no biological link to coagulation

Recommendation for all 8: Hold — no clinical, mechanistic, or literature basis to pursue.

Norway Market Information

Susoctocog alfa is not currently marketed in Norway (0 authorizations on record). No license or dosage form data is available in this pack.

Safety Considerations

Please refer to the package insert for safety information.

(Key warnings, contraindications, and drug interaction data were not available in this evidence pack — this is flagged as a Blocking data gap, DG001, requiring TFDA/regulatory label retrieval before any safety-stage decision.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Only the AHA/acquired-coagulation-factor-deficiency signal (ranks 4–5) is backed by real clinical and observational evidence (L3), and it is mechanistically coherent with the drug's known replacement-therapy action — this largely represents confirmation/extension of an already-established use rather than a novel repurposing hypothesis. The other 8 TxGNN top-score predictions lack any supporting evidence and should be held.

To proceed, the following is needed:

Retrieve official TFDA/EMA/FDA label (Obizur/OBIZER) to fill the Blocking safety data gap (DG001) — warnings, contraindications, DDI
Retrieve DrugBank MOA data (DG002) to formally document mechanism
Confirm and record the drug's actual original approved indication(s), currently missing from regulatory fields
Clarify Norway-specific regulatory pathway, since the product is not currently marketed there
If pursuing the broader "acquired coagulation factor deficiency" extension, seek disease-specific case data beyond AHA to support that generalization
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.